Gelesis
Boston
About Gelesis
Gelesis is a clinical stage biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients. Gelesis100, our lead product, is an orally- administered smart pill which is constructed of materials that are General Recognized as Safe (GRAS) by the Food and Drug Administration (FDA). Each Gelesis100 capsule contains thousands of hydrogel particles approximately the size of a grain of salt that expand to 100 times their dry weight. The pill is designed to act mechanically in the stomach and small intestine to increase satiety and decrease hunger, resulting in reduced caloric intake and weight loss. <a href="http://www.gelesis.com/">Gelesis</a> was founded in 2006 in Boston, Massachusetts
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $312.8M
- Funding stage: IPO
- Last round: Post-IPO Debt (Jan 2022)
- Ticker: otcpink:GLSH
- Website: gelesis.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Diabetes, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/gelesis-152835 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.